CN115068417A - Enoxaparin sodium injection and preparation method thereof - Google Patents
Enoxaparin sodium injection and preparation method thereof Download PDFInfo
- Publication number
- CN115068417A CN115068417A CN202210833034.3A CN202210833034A CN115068417A CN 115068417 A CN115068417 A CN 115068417A CN 202210833034 A CN202210833034 A CN 202210833034A CN 115068417 A CN115068417 A CN 115068417A
- Authority
- CN
- China
- Prior art keywords
- enoxaparin sodium
- injection
- rosmarinic acid
- mixed solution
- sodium injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an enoxaparin sodium injection and a preparation method thereof, wherein the enoxaparin sodium injection comprises enoxaparin sodium, rosmarinic acid, grape seed extract, mannitol, polyvinylpyrrolidone and water for injection. According to the invention, rosmarinic acid is a macromolecular structure substance containing polyhydroxy and a carboxyl, has strong oxidation resistance, so that the enoxaparin sodium injection is kept stable, when sodium hydroxide or potassium hydroxide is added into the enoxaparin sodium injection to adjust the pH value of the solution, because the rosmarinic acid molecular structure contains the carboxyl, the rosmarinic acid and the sodium hydroxide or potassium hydroxide form a salt, rosmarinic acid and rosmarinic acid salt form a buffer system, so that the stability of the pH value of the solution can be kept for a long time, and the enoxaparin sodium in the injection is kept stable; the grape seed extract is a natural antioxidant, and the grape seed extract and the rosmarinic acid are matched to generate a synergistic effect, so that the stability of the enoxaparin sodium injection is greatly improved.
Description
Technical Field
The invention belongs to the technical field of biological medicine, and particularly relates to an enoxaparin sodium injection and a preparation method thereof.
Background
Enoxaparin sodium is low molecular weight heparin sodium produced by alkali cracking of heparin benzyl ester sodium derivative obtained by esterifying heparin sodium extracted from porcine intestinal mucosa. It consists of many complex, undefined oligosaccharides. As is currently known, most oligosaccharides have 4-enolpyranonic acids at the non-reducing end of the sugar chain. Having a 1, 6-dehydrated structure at the reducing end of the sugar chain accounts for 15 to 25% of the total sugar. The weight average molecular weight of enoxaparin sodium is 3800-5000, the oligosaccharide mass percent with molecular weight <2000 is 12-20%, and the oligosaccharide mass percent with molecular weight 2000-8000 is 68-82%. The titer of the anti-Xa factor per mg is 90-125IU according to dry product; the ratio of anti-Xa to anti-IIa is between 3.3 and 5.3. Enoxaparin sodium can effectively prevent venous thromboembolism and pulmonary embolism, can be used for thrombosis before and after orthopedic surgery and neurosurgery, can greatly reduce the risk of suffering from stroke, can more effectively reduce death, heart failure, recurrent angina and the like of unstable coronary syndrome patients, can reduce hypertriglyceridemia, and can effectively solve the side effects of bleeding, osteoporosis, induced thrombocytopenia and the like of ordinary unfractionated heparin and derivatives thereof after long-term use.
At present, the normal production process of the enoxaparin sodium injection comprises the following steps: dissolving enoxaparin sodium in cooled water for injection, sterile filtering, bottling, inspecting, and packaging. The enoxaparin sodium injection produced by the process has poor stability including greatly reduced pH value, obvious color change and the like in the process of placing or accelerating experiment.
In view of the above, there is a need to provide an enoxaparin sodium injection to solve the above problems.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides an enoxaparin sodium injection and a preparation method thereof. Solves the problems that the enoxaparin sodium injection liquid medicine produced by the prior enoxaparin sodium injection general production process has poor stability, including great reduction of pH value, obvious change of color and the like.
One object of the present invention is to provide an enoxaparin sodium injection.
An enoxaparin sodium injection, wherein the enoxaparin sodium injection comprises enoxaparin sodium, rosmarinic acid, grape seed extract, mannitol, polyvinylpyrrolidone and water for injection.
Further, by mass percentage, the dosage of the enoxaparin sodium is 8-12%, the dosage of the rosmarinic acid is 1-3%, the dosage of the grape seed extract is 0.5-0.8%, the dosage of the mannitol is 1-2%, the dosage of the polyvinylpyrrolidone is 0.05-0.1%, and the balance is water for injection.
Furthermore, by mass percentage, the enoxaparin sodium is 10%, the rosmarinic acid is 3%, the grape seed extract is 0.7%, the mannitol is 1.5%, the polyvinylpyrrolidone is 0.07%, and the balance is water for injection.
Further, the pH value of the enoxaparin sodium injection is 6.0-7.5.
Further, the pH may be adjusted by adding sodium hydroxide or potassium hydroxide.
The second purpose of the invention is to provide a preparation method of enoxaparin sodium injection.
The preparation method of enoxaparin sodium injection described in any one of the above, including the following steps:
s1, dissolving rosmarinic acid and polyvinylpyrrolidone in water for injection according to the formula amount, and then stirring and mixing uniformly to obtain a first mixed solution;
s2, adding enoxaparin sodium and grape seed extract in a formula amount into the first mixed solution, and continuously stirring and uniformly mixing to obtain a second mixed solution;
s3, adding mannitol in a formula amount into the second mixed solution, continuously stirring and uniformly mixing, and adjusting the pH value of the solution to 6.0-7.5 to obtain a third mixed solution;
and S4, filtering the third mixed solution through an aseptic filtering system, and filling the third mixed solution in an aseptic manner to obtain the enoxaparin sodium injection.
Further, in step S1, the rotation speed of the stirring is 100-120 rpm, and the time is 30-60 min.
Further, in step S2, the rotation speed of the stirring is 60-80 rpm, and the time is 50-80 min.
Further, in step S3, the rotation speed of the stirring is 30-50 rpm, and the time is 15-30 min.
Compared with the prior art, the invention has the following advantages:
in the invention, the enoxaparin sodium injection comprises enoxaparin sodium, rosmarinic acid, grape seed extract, mannitol, polyvinylpyrrolidone and water for injection. The rosmarinic acid is a macromolecular structure substance containing polyhydroxy and a carboxyl, and has stronger oxidation resistance due to containing phenolic hydroxyl, so that the enoxaparin sodium injection is kept stable, when sodium hydroxide or potassium hydroxide is added into the enoxaparin sodium injection to adjust the pH value of the solution, the rosmarinic acid molecular structure contains the carboxyl, and forms a salt with the sodium hydroxide or potassium hydroxide, and the rosmarinic acid and rosmarinic acid salt form a buffer system, so that the pH value of the solution can be kept stable for a long time, and the enoxaparin sodium in the injection is kept stable; the grape seed extract is a natural antioxidant, and is matched with the rosmarinic acid to generate a synergistic effect, so that the stability of the enoxaparin sodium injection is greatly improved; mannitol is used as an injection auxiliary material, can adjust the osmotic pressure of the enoxaparin sodium injection, and simultaneously improves the stability of the injection; the polyvinylpyrrolidone is a cosolvent, can improve the solubility of the enoxaparin sodium and prevent the enoxaparin sodium from crystallizing out, and the components have mutual synergistic effect, so that the enoxaparin sodium injection has excellent stability.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below. It is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments, and all other embodiments obtained by those skilled in the art without any inventive work are within the scope of the present invention.
The conventional reagents and equipment used in the present invention are commercially available unless otherwise specified.
Example 1
The enoxaparin sodium injection comprises, by mass, 8% of enoxaparin sodium, 1% of rosmarinic acid, 0.5% of grape seed extract, 1% of mannitol, 0.05% of polyvinylpyrrolidone and the balance of water for injection.
The preparation method of the enoxaparin sodium injection comprises the following steps:
s1, dissolving rosmarinic acid and polyvinylpyrrolidone in water for injection according to the formula amount, and then stirring and mixing uniformly to obtain a first mixed solution, wherein the stirring speed is 100-120 rpm, and the stirring time is 30-60 min;
s2, adding enoxaparin sodium and a grape seed extract in a formula amount into the first mixed solution, and continuously stirring and uniformly mixing to obtain a second mixed solution, wherein the stirring speed is 60-80 rpm, and the stirring time is 50-80 min;
s3, adding mannitol with the formula amount into the second mixed solution, continuously stirring and uniformly mixing, and adjusting the pH value of the solution to 6.3 to obtain a third mixed solution, wherein the stirring speed is 30-50 rpm, and the stirring time is 15-30 min;
s4, filtering the third mixed solution through a sterile filtering system, and filling in a sterile manner to obtain the enoxaparin sodium injection.
Example 2
The enoxaparin sodium injection comprises, by mass, 9% of enoxaparin sodium, 1.5% of rosmarinic acid, 0.6% of grape seed extract, 1.2% of mannitol, 0.06% of polyvinylpyrrolidone and the balance of water for injection.
The preparation method of the enoxaparin sodium injection comprises the following steps:
s1, dissolving rosmarinic acid and polyvinylpyrrolidone in water for injection according to the formula amount, and then stirring and mixing uniformly to obtain a first mixed solution, wherein the stirring speed is 100-120 rpm, and the stirring time is 30-60 min;
s2, adding enoxaparin sodium and a grape seed extract in a formula amount into the first mixed solution, and continuously stirring and uniformly mixing to obtain a second mixed solution, wherein the stirring speed is 60-80 rpm, and the stirring time is 50-80 min;
s3, adding mannitol with the formula amount into the second mixed solution, continuously stirring and uniformly mixing, and adjusting the pH value of the solution to 6.5 to obtain a third mixed solution, wherein the stirring speed is 30-50 rpm, and the stirring time is 15-30 min;
and S4, filtering the third mixed solution through an aseptic filtering system, and filling the third mixed solution in an aseptic manner to obtain the enoxaparin sodium injection.
Example 3
An enoxaparin sodium injection, by mass percent, the enoxaparin sodium is 10%, the rosmarinic acid is 3%, the grape seed extract is 0.7%, the mannitol is 1.5%, the polyvinylpyrrolidone is 0.07%, and the balance is water for injection.
The preparation method of the enoxaparin sodium injection comprises the following steps:
s1, dissolving rosmarinic acid and polyvinylpyrrolidone in water for injection according to the formula amount, and then stirring and mixing uniformly to obtain a first mixed solution, wherein the stirring speed is 100-120 rpm, and the stirring time is 30-60 min;
s2, adding enoxaparin sodium and a grape seed extract in a formula amount into the first mixed solution, and continuously stirring and uniformly mixing to obtain a second mixed solution, wherein the stirring speed is 60-80 rpm, and the stirring time is 50-80 min;
s3, adding mannitol with the formula amount into the second mixed solution, continuously stirring and uniformly mixing, and adjusting the pH value of the solution to 6.8 to obtain a third mixed solution, wherein the stirring speed is 30-50 rpm, and the stirring time is 15-30 min;
and S4, filtering the third mixed solution through an aseptic filtering system, and filling the third mixed solution in an aseptic manner to obtain the enoxaparin sodium injection.
Example 4
The enoxaparin sodium injection comprises, by mass, 12% of enoxaparin sodium, 3% of rosmarinic acid, 0.8% of grape seed extract, 2% of mannitol, 0.1% of polyvinylpyrrolidone, and the balance of water for injection.
The preparation method of the enoxaparin sodium injection comprises the following steps:
s1, dissolving rosmarinic acid and polyvinylpyrrolidone in water for injection according to the formula amount, and then stirring and mixing uniformly to obtain a first mixed solution, wherein the stirring speed is 100-120 rpm, and the stirring time is 30-60 min;
s2, adding enoxaparin sodium and grape seed extract according to the formula ratio into the first mixed solution, and continuously stirring and uniformly mixing to obtain a second mixed solution, wherein the stirring speed is 60-80 rpm, and the stirring time is 50-80 min;
s3, adding mannitol with the formula amount into the second mixed solution, continuously stirring and uniformly mixing, and adjusting the pH value of the solution to 7.0 to obtain a third mixed solution, wherein the stirring speed is 30-50 rpm, and the stirring time is 15-30 min;
and S4, filtering the third mixed solution through an aseptic filtering system, and filling the third mixed solution in an aseptic manner to obtain the enoxaparin sodium injection.
Comparative example 1
The formula of the enoxaparin sodium injection is not added with rosmarinic acid, and the preparation method is the same as that of the example 3.
Comparative example 2
The formula of the enoxaparin sodium injection is not added with grape seed extract, and the preparation method is the same as that of the example 3.
Comparative example 3
The preparation method of the enoxaparin sodium injection is the same as that in example 3, and vitamin C is used for replacing rosmarinic acid in the formula of the enoxaparin sodium injection.
Example 5
The enoxaparin sodium injection prepared in examples 1 to 4 and comparative examples 1 to 3 was subjected to a long-term stability test, the sample was left under long-term conditions (25 ± 2 ℃, 60 ± 10% RH) for 6 months, samples were taken at months 0, 2, 4 and 6 respectively, pH was measured, and the color and state of the enoxaparin sodium injection were observed at the same time, with the results shown in table 1 below:
TABLE 1 Long-term stability test results for enoxaparin sodium injection
As can be seen from the results in table 1, after the enoxaparin sodium injection prepared in examples 1 to 4 is left for 6 months, the pH value of the solution is almost unchanged, and the solution is colorless, clear and transparent and has good stability;
the difference between the comparative example 1 and the example 3 is that no rosmarinic acid is added, and as a result, the prepared enoxaparin sodium injection is found that the pH value of the solution is obviously reduced after the prepared enoxaparin sodium injection is placed for 6 months, the solution becomes light yellow after the 6 th month, the stability of the enoxaparin sodium injection prepared in the example 3 is that the rosmarinic acid is a macromolecular structure substance containing polyhydroxy and one carboxyl, and has stronger oxidation resistance because the rosmarinic acid contains phenolic hydroxyl, so that the enoxaparin sodium injection is stable, and when the pH value of the solution is adjusted by adding sodium hydroxide or potassium hydroxide into the enoxaparin sodium injection, the rosmarinic acid and the rosmarinic acid salt form a buffer system because the rosmarinic acid contains the carboxyl in the molecular structure, and forms a salt with sodium hydroxide or potassium hydroxide, so that the stability of the pH value of the solution can be maintained for a long time;
the difference between the comparative example 2 and the example 3 is that no grape seed extract is added, and the result shows that the prepared enoxaparin sodium injection is reduced in pH value after being placed for 6 months, and becomes light yellow after 6 months, because the grape seed extract is a natural antioxidant and is matched with rosmarinic acid, and the grape seed extract and the rosmarinic acid generate a synergistic effect, so that the stability of the enoxaparin sodium injection is greatly improved;
comparative example 3 is different from example 3 in that vitamin C is used instead of rosmarinic acid, and it was found that the prepared enoxaparin sodium injection was decreased in pH after being left for 6 months, and the solution became light yellow after 6 months, because vitamin C has a certain antioxidant property, but lacks carboxyl group, and cannot form a buffer system, resulting in an unstable solution system.
Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art will understand that: any person skilled in the art can modify or easily conceive the technical solutions described in the foregoing embodiments or equivalent substitutes for some technical features within the technical scope of the present disclosure; such modifications, changes or substitutions do not depart from the spirit and scope of the embodiments of the present invention, and they should be construed as being included therein.
Claims (9)
1. The enoxaparin sodium injection is characterized by comprising enoxaparin sodium, rosmarinic acid, grape seed extract, mannitol, polyvinylpyrrolidone and water for injection.
2. The enoxaparin sodium injection as claimed in claim 1, wherein the enoxaparin sodium is 8-12 wt%, the rosmarinic acid is 1-3 wt%, the grape seed extract is 0.5-0.8 wt%, the mannitol is 1-2 wt%, the polyvinylpyrrolidone is 0.05-0.1 wt%, and the balance is water for injection.
3. The enoxaparin sodium injection of claim 2, wherein the enoxaparin sodium is 10% by weight, the rosmarinic acid is 3% by weight, the grape seed extract is 0.7% by weight, the mannitol is 1.5% by weight, the polyvinylpyrrolidone is 0.07% by weight, and the balance is water for injection.
4. The enoxaparin sodium injection of claim 1, wherein the pH of enoxaparin sodium injection is 6.0-7.5.
5. The enoxaparin sodium injection of claim 4, wherein the pH is adjusted by adding NaOH or KOH.
6. The method of any one of claims 1-5, comprising the steps of:
s1, dissolving rosmarinic acid and polyvinylpyrrolidone in water for injection according to the formula amount, and then stirring and mixing uniformly to obtain a first mixed solution;
s2, adding enoxaparin sodium and grape seed extract in a formula amount into the first mixed solution, and continuously stirring and uniformly mixing to obtain a second mixed solution;
s3, adding mannitol in a formula amount into the second mixed solution, continuously stirring and uniformly mixing, and adjusting the pH value of the solution to 6.0-7.5 to obtain a third mixed solution;
and S4, filtering the third mixed solution through an aseptic filtering system, and filling the third mixed solution in an aseptic manner to obtain the enoxaparin sodium injection.
7. The method for preparing enoxaparin sodium injection of claim 6, wherein in step S1, the rotation speed of stirring is 100-120 rpm for 30-60 min.
8. The method for preparing enoxaparin sodium injection of claim 6, wherein in step S2, the rotation speed of stirring is 60-80 rpm for 50-80 min.
9. The method for preparing enoxaparin sodium injection of claim 6, wherein in step S3, the rotation speed of stirring is 30-50 rpm for 15-30 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210833034.3A CN115068417A (en) | 2022-07-14 | 2022-07-14 | Enoxaparin sodium injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210833034.3A CN115068417A (en) | 2022-07-14 | 2022-07-14 | Enoxaparin sodium injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115068417A true CN115068417A (en) | 2022-09-20 |
Family
ID=83259156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210833034.3A Pending CN115068417A (en) | 2022-07-14 | 2022-07-14 | Enoxaparin sodium injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068417A (en) |
-
2022
- 2022-07-14 CN CN202210833034.3A patent/CN115068417A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2833898C2 (en) | ||
| EP1132081B1 (en) | Process for preparing cellulose capsule using mixed solution of pectin and glycerin | |
| US9475888B2 (en) | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use | |
| JP2003522796A (en) | Anti-adhesive carbohydrates | |
| NZ584919A (en) | Dilute filtration sterilization process for viscoelastic biopolymers | |
| WO2021143595A1 (en) | Low-molecular-weight tremella aurantialba glucuronic acid-xylomannan, and preparation method therefor and use thereof | |
| PT1492821E (en) | Iron dextrin compounds for the treatment of iron deficiency anaemia | |
| CN110699219A (en) | A compound wine containing gamma-aminobutyric acid and hyaluronic acid or its salt, and its preparation method | |
| US10023659B2 (en) | Processes for the production of chemically-modified heparins | |
| EP2511302A1 (en) | Method for manufacturing purified hyaluronic acids | |
| CN115068417A (en) | Enoxaparin sodium injection and preparation method thereof | |
| CN104013570B (en) | A kind of enoxaparin sodium injection and its preparation technology | |
| KR20140072716A (en) | Film having improved haze | |
| CN111234322B (en) | High-oxidation-resistance edible packaging film and preparation method thereof | |
| CN109575156B (en) | Purification method of low-molecular heparin | |
| EP0233615A2 (en) | Aqueous preparation and method of preparation thereof | |
| EP2155161B1 (en) | Stable liquid composition of chondroitinsulfate and glucosamine | |
| EP0593605B1 (en) | Method of preparing starch esters for clinical, in particular parenteral, applications | |
| CN111067009A (en) | Method for improving thermal stability of beet red pigment | |
| DE69931038T2 (en) | NEW POLYSACCHARIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL COMPOSITIONS THEREOF CONTAINING THEM AS AN ACTIVE INGREDIENT | |
| CN111171344A (en) | Preparation method of alcohol-induced low-alkali konjac gel | |
| US7618652B2 (en) | Glycosaminoglycan anticoagulants derived from fish | |
| DE19859771C1 (en) | Water-soluble, stable pyruvic acid (salt) -containing formulation | |
| CN108686004B (en) | Children phlegm-eliminating cough-relieving granules and preparation method thereof | |
| CN110498863A (en) | Climbing fig leaf polyose and preparation method thereof and preparing the purposes in anticomplement medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |